Lilly cuts self-pay prices for two Foundayo doses through the end of 2026
Two doses of the oral GLP-1 pill cost $50 to $100 less a month for people paying cash, but the reduction and the savings card both end December 31, 2026.
Lilly has temporarily lowered the self-pay price of two doses of Foundayo (orforglipron), its oral GLP-1 pill, according to the company's coverage and savings page. The 2.5 mg dose is listed at $149 a month and the 5.5 mg dose at $199 a month, both "for a limited time, through December 31, 2026" [1].
Those are cuts from the regular self-pay prices Lilly lists for the same doses: $199 a month for 2.5 mg and $299 a month for 5.5 mg, or $50 and $100 less per month [1]. The same page lists regular self-pay prices of $149 for 0.8 mg, $299 for 9 mg, and $349 for 14.5 mg and 17.2 mg [1]. Only the 2.5 mg and 5.5 mg doses are described as temporarily reduced [1].
Lilly has not published a start date for the lower prices and has not given a public reason for the change [1]. Nothing has been published about what the two doses will cost after December 31, 2026 [1].
Patients in the r/FoundayoPill community have been discussing the new pricing [2]. Lilly has not said whether customers who filled a prescription at the older prices can get the difference back [1]. The savings page does describe a post-transaction reimbursement process for people whose discount could not be verified at the pharmacy counter, but those terms are tied to a 45-day refill requirement for the 14.5 mg and 17.2 mg doses, not to the temporary price reduction [1].
The lower self-pay prices sit alongside Lilly's other programs. People with commercial insurance that covers Foundayo can pay as little as $25 a month with the Foundayo Savings Card, capped at $100 in savings per month, $1,000 per calendar year, and up to 10 fills per year [1]. People with commercial insurance that does not cover Foundayo can pay as low as $149 for the 0.8 mg and 2.5 mg doses, $199 for 5.5 mg, or $299 for 9 mg, 14.5 mg and 17.2 mg [1]. Government beneficiaries, including people on Medicare, Medicaid, TRICARE and VA coverage, are excluded from the savings card [1]. The card and its savings end on December 31, 2026, and Lilly says it can change or end the terms at any time without notice [1]. Separately, eligible Medicare Part D patients can get Foundayo for $50 a month through the Medicare GLP-1 Bridge Program if they meet the program's clinical criteria [1].
Why it matters for patients
For anyone paying out of pocket, the change means $50 to $100 less a month on two of the six listed doses for as long as the temporary prices last [1]. The other doses on the self-pay list are unchanged [1].
Because the reduction is described as temporary and runs only through December 31, 2026, the price a patient pays in January is not yet known [1]. The savings card used by people with commercial insurance also expires the same day [1], so cash-paying and insured patients face the same unanswered question about next year.
Lilly's terms state that the savings card program can be amended, revoked or terminated at any time, without notice, and for any reason [1]. That means today's prices and card terms are not locked in.
Refill timing can also affect what a patient pays. The $299 price for the 14.5 mg and 17.2 mg doses is a purchase offer that requires the refill to be completed within 45 days of the delivery date of the previous fill; a later refill means the offer does not apply [1].
What happens next
December 31, 2026 is the only date Lilly has attached to the temporary prices and to the savings card [1]. No information about Foundayo pricing or savings in 2027 has been published [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.